Skip to main content
OpenTrials
Completed

NCT Number: NCT06122597

A Clinical Trial to Evaluate the Efficacy of ConcenTrace to Buffer pH Levels Within the Body.

This virtual single-arm trial will last 12 weeks. Participants will take the drops daily and complete questionnaires at Baseline, Week 4, Week 8, and Week 12.

Urine pH measurements will be taken at Baseline, Week 4, Week 8, and Week 12 using pH test strips.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

pH

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Santa Monica, California, 90404, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female. Aged 18+. Generally healthy - don't live with any uncontrolled disease. Willing to maintain their standard dietary pattern, activity level, and body weight for the duration of the study.

Exclusion criteria

  • Anyone with a pre-existing chronic condition that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.

Anyone with known severe allergic reactions. Women who are pregnant, breastfeeding, or attempting to become pregnant. Anyone unwilling to follow the study protocol.

Treatment and study plan

ConcenTrace

Other

The product contains concentrated seawater from Utah's inland sea.

Primary outcomes

  1. Changes in urine pH levels. [Timeframe: Baseline to Week 12]

    Time frame: 12 weeks

    Participants will use pH test strips to measure urine pH. Changes in urine pH will be evaluated.

Secondary outcomes

  1. Change in score on the Metabolic Screening Questionnaire.

    Time frame: 12 weeks

    A Metabolic Screening Questionnaire (MSQ) was developed by the Toronto Centre for Naturopathic Medicine. The symptoms represented on a MSQ represent symptoms commonly associated with inflammation and toxicity. Participants will rate frequency and intensity of applicable symptoms according to the following scores:

    • Absent or rare symptoms - 0 points
    • Occasional, mild symptoms - 1 point
    • Occasional, severe symptoms - 2 points
    • Frequent, mild symptoms - 3 points
    • Frequent, severe symptoms - 4 points

Sponsors and collaborators

Lead sponsor

Trace Minerals

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Nov 8, 2023
Registry last updated
Aug 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.